Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00381680 · OUTCOME

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia · Source last updated 2024-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
End of Block 3 (105 days) of Induction therapy

What was measured

Percentage of patients who had minimal residual disease (MRD) \< 0.01% among those with isolated BM or combined BM relapse \>= 36 months and had successful MRD determinations at End Block 3.

Analysis population: This analysis is limited to all eligible patients with isolated BM or combined BM relapse \>= 36 months and had successful MRD determinations at End Block 3.

Groups in this outcome

Regimen A

Standard VCR dosing (1.5 mg/m\^2, max 2mg)

Regimen B

Intensive VCR dosing (2 mg/m\^2, max 2.5 mg)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen A70
Regimen B27

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Regimen A81.4Not reportedNot reportedNot reportedNot reported
Regimen B88.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        81.4
      2. group Id
        OG001
        value
        88.9
denoms
  1. counts
    1. group Id
      OG000
      value
      70
    2. group Id
      OG001
      value
      27
    units
    Participants
description
Percentage of patients who had minimal residual disease (MRD) \< 0.01% among those with isolated BM or combined BM relapse \>= 36 months and had successful MRD determinations at End Block 3.
groups
  1. description
    Standard VCR dosing (1.5 mg/m\^2, max 2mg)
    id
    OG000
    title
    Regimen A
  2. description
    Intensive VCR dosing (2 mg/m\^2, max 2.5 mg)
    id
    OG001
    title
    Regimen B
param Type
NUMBER
population Description
This analysis is limited to all eligible patients with isolated BM or combined BM relapse \>= 36 months and had successful MRD determinations at End Block 3.
reporting Status
POSTED
time Frame
End of Block 3 (105 days) of Induction therapy
title
Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice